
Novo Nordisk has a history of marketing drugs under different names for treatments of obesity and diabetes, respectively. Novo Nordisk's biggest competitor, Eli Lilly, is now pondering a similar move, writes industry media Fiercepharma.
The US-based company is targeting the same markets as Novo's drug, semaglutide, which is branded as either Ozempic or Wegovy depending on whether the treatment is for diabetes or obesity. Eli Lilly is considering the same approach, said the company's CEO, Dave Ricks, at J.P. Morgan's annual healthcare conference.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app